# A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

> **NCT00264732** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 251 (actual)

## Conditions studied

- Uterine Cervical Dysplasia

## Interventions

- **DRUG:** Amolimogene
- **DRUG:** Amolimogene
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00264732
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2013-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264732, "A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00264732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*